Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?

References

• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis – a geographically based study. Brain112, 133–146 (1989).
   PubMed Web of Science ®Google Scholar
• Poser S, Kurtzke JF, Poser W et al. Survival in multiple sclerosis. J. Clin. Epidemiol. 42, 159–168 (1989).
   PubMed Web of Science ®Google Scholar
• Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology44, 1901–1907 (1994).
   PubMed Web of Science ®Google Scholar
• Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Harrison’s Principles of Internal Medicine. 13th Ed. Isselbacher KJ, Braunwald E, Wilson JD et al. (Eds). McGraw-Hill, Inc. NY, USA, 2281–2294 (1994).
   Google Scholar
• Reumont MJ, Deluca SA. Neuroimaging evaluation in multiple sclerosis. Am. Fam. Physician 48(2), 273–276 (1993).
   PubMed Web of Science ®Google Scholar
• Hibbard PL. The use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann. Neurol. 36(S2), S218–S130 (1994).
   Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinschenker BG. Medical progress: multiple sclerosis. N. Eng. J. Med. 343, 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Ellington L et al. Cognitive dysfunction in multiple sclerosis. II. Impact on unemployment and social functioning. Neurology41, 692–696 (1991).
   PubMed Web of Science ®Google Scholar
• Bauer HJ, Firnhaber W, Winkler W. Prognostic criteria in multiple sclerosis. Ann. NY Acad. Sci. 122(1), 542–551 (1965).
   PubMed Web of Science ®Google Scholar
• LaRoca N, Kalb R, Kendall P et al. The role of disease and demographic factors in the employment of patients with multiple sclerosis. Arch. Neurol.39, 256 (1982).
   PubMedGoogle Scholar
• IFNβ Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Goodkin DE, Jacobs LD et al. Impact of interferon β-1a on neurologic disability in relapsing multiple sclerosis. Neurology49, 358–363 (1997).
   PubMed Web of Science ®Google Scholar
• The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology45, 1277–1285 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo controlled trial. Neurology45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Larson LN. Cost determination and analysis. In: Principles of Pharmacoeconomics. Bootman JL, Townsend RJ, McGahan WF (Eds). Harvey Whitney Books Co, OH, USA, 44–59 (1996).
   Google Scholar
• Rice DP. Cost-of-illness studies: fact or fiction? Lancet344, 1519–1520 (1994).
   PubMed Web of Science ®Google Scholar
• Hodgson TA. Cost of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 6(6), 536–552 (1994)
   PubMed Web of Science ®Google Scholar
• Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy8, 317–323 (1987).
   Web of Science ®Google Scholar
• Drummond M. Cost of illness studies: a major headache? Pharmacoeconomics 2(1), 1–4 (1992).
   PubMedGoogle Scholar
• Holmes BA, Madgwick T, Bates D. The cost of MS. Br. J. Med. Econ. 8, 181–193 (1995).
   Google Scholar
• Blumhardt LD, Wood C. The economics of MS: a cost of illness study. Br. J. Med. Econ. 10, 99–118 (1996).
   Google Scholar
• Midgard R, Rise T, Nyland H. Impairment, disability and handicap in multiple sclerosis. A cross-sectional observational study in More and Romsdal County, Norway. J. Neurol. 337–344 (1996).
   PubMed Web of Science ®Google Scholar
• Asche CV, Ho E, Chan B et al. Economic consequences of MS for Canadians. Acta Neurol. Scand. 95, 268–274 (1997).
   PubMed Web of Science ®Google Scholar
• Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeoconomics13, 597–606 (1998).
   PubMed Web of Science ®Google Scholar
• Bourdette DN, Prochazka AV, Mitchell W, Licari P, Burks J. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch. Phys. Med. Rehabil. 74, 26–31 (1993).
   PubMed Web of Science ®Google Scholar
• Stolp-Smith KA, Atkinson EJ, Campion ME, OBrien PC, Rodriguez M. Health care utilization in multiple sclerosis: a population-based study in Olmstead County, MN. Neurology50, 1594–1600 (1998).
   PubMed Web of Science ®Google Scholar
• The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part I: cost of illness. Can. J. Neurol. Sci. 25, 23–30 (1998).
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 6, 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. Utilization and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J. Neurol. Neurosurg. Psychiatry64, 444–450 (1998).
   PubMed Web of Science ®Google Scholar
• Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. A quantitative study of unpaid caregiving in multiple sclerosis. Mult. Scler. 6, 274–279 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M et al. Economic evaluation of multiple sclerosis in the U.K., Germany and France. Pharmacoeconomics13, 607–622 (1998).
   PubMed Web of Science ®Google Scholar
• Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur. J. Neurol. 8, 27–35 (2001).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Smala A, Jonsson B. German Cost of MS Study Group. Costs and quality of life in multiple sclerosis: an observational study in Germany. HEPAC 2, 60–68 (2001).
   Google Scholar
• Amato MP, Battaglia MA, Caputo D et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J. Neurol.249, 152–163 (2002).
   PubMed Web of Science ®Google Scholar
• Orlewska E, Mierzejewski P, Zaborski J et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur. J. Neurol. 12, 31–39 (2005).
   PubMed Web of Science ®Google Scholar
• Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics15(3), 229–240 (1999).
   PubMed Web of Science ®Google Scholar
• Kobelt G. Economic evidence in multiple sclerosis: a review. Eur. J. Health Econ. (Suppl. 1), S54–S62 (2004).
   Google Scholar
• Parwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult. Scler.11, 232–239 (2005).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Puglatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol. (Suppl. 1), 63–67 (2005)
   PubMed Web of Science ®Google Scholar
• Drummond MF, O’Brien B, Stoddart LG et al. Methods for Economic Evaluation of Health Care Programmes (2nd Ed.). Oxford, Oxford University Press, UK, 209–212 (1997).
   Google Scholar
• Koopmanschap MA, Rutten FFH, van Ieveld BM et al. The friction-cost method for estimating the indirect costs of disease. J. Health Econ. 14, 171–189 (1995).
   PubMed Web of Science ®Google Scholar
• Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost–effectiveness analysis. In: Costs–Effectiveness in Health and Medicine. Gold M, Siegel J et al. (Eds). Oxford University Press, NY, USA, 176–213 (1996).
   Google Scholar
• Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs in cost–effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 6, 511–514 (1997)
   PubMed Web of Science ®Google Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics13, 1–7 (1998).
   PubMed Web of Science ®Google Scholar
• Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Economic Evaluation in Health Care: Merging Theory with Practice. Drummond MF, Mcguire A (Eds). Oxford, Oxford University Press, UK (2001).
   Google Scholar
• Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department of Human Services (1995).
   Google Scholar
• Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. 2nd Ed. Ottawa, ON, Canada (1997).
   Google Scholar
• Riteco JA, De Heij LJM, van Luijn JCF et al. Dutch guidelines: pharmacoeconomic research guidelines Amstelveen: CvZ (1999)
   Google Scholar
• Siegel JE, Torrance GW, Russel LB et al. Guidelines for pharmacoeconomic studies . Pharmacoeconomics11(2), 159–168 (1997)
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB et al. (Eds). Cost–effectiveness in health and medicine. Oxford University Press, NY, USA, 181–183 (1996)
   Google Scholar
• Koopmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, Severens H. Measuring productivity changes in economic evaluation. Setting the research agenda. Pharmacoeconomics23(1), 47–54 (2005).
   PubMed Web of Science ®Google Scholar
• Smith K, Wright K. Informal care and economic appraisal: a discussion of possible methodological approaches. Health Econ. 3, 137–148 (1994).
   PubMed Web of Science ®Google Scholar
• Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 5, 13–23 (1996).
   PubMed Web of Science ®Google Scholar
• van den Berg B, Brouwer B, Koopmanschap MA. Economic evaluation of informal care. An overview of methods and applications. Eur. J. Health Econ.5(1), 36–45 (2004).
   PubMedGoogle Scholar
• Torrance G. Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1–30 (1998).
   Google Scholar